FCMI
NTLA icon

Foresite Capital Management III’s Intellia Therapeutics NTLA Stock Holding History

Foresite Capital Management III’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-150,000
Closed -$2.11M – 29
2017
Q1 		$2.11M Sell
150,000
-553,563
-79% -$7.43M 0.81% 19
2016
Q4 		$9.22M Sell
703,563
-60,125
-8% -$903K 4.01% 7
2016
Q3 		$13M Hold
763,688
– – 6.08% 5
2016
Q2 		$16.3M Buy
+763,688
New +$20.3M 11.19% 4

Other funds holding NTLA

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Foresite Capital Management III's NTLA Position: Q2 2017 in Review

Foresite Capital Management III sold out of Intellia Therapeutics (NTLA) in Q2 2017, closing a stake of 150,000 shares — an estimated $2.11M sold.

Foresite Capital Management III first reported a position in NTLA in Q2 2016 and held it in 4 quarters. The position peaked at $16.3M in Q2 2016. 85 funds tracked by Wall St. Rank hold NTLA as of Q2 2017.

  • Foresite Capital Management III reported no remaining Intellia Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 150,000 Intellia Therapeutics shares in Q2 2017, an estimated $2.11M.
  • Foresite Capital Management III first reported a position in Intellia Therapeutics in Q2 2016 and held it in 4 quarters.
  • Foresite Capital Management III's Intellia Therapeutics position peaked at $16.3M in Q2 2016.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2017.

Based on Foresite Capital Management III's 13F filing for Q2 2017, filed 14 Aug 2017.